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STRUCTURED ABSTRACT 
Aim: To investigate self-monitoring of blood glucose (SMBG) behaviour among non-
insulin treated patients with type 2 diabetes mellitus, and to evaluate associations with 
glycaemic control. Methods: Eligible patients in 23 GP practices in Tayside, Scotland, 
were identified (18-75 years, no insulin treatment, SMBG reagent strips dispensed in 
2009). Consenting patients were administered questionnaires addressing SMBG 
behavior:  these primary data were record-linked to clinical data (including HbA1c) from 
a validated population-based diabetes clinical information system, then anonymised. 
Results: Among 629 eligible patients, 207 were interviewed and analysed. Mean SMBG 
reagent strips dispensed in 12 months was 268. Eighty (38.8%) patients took no action in 
response to perceived high test results, or simply checked later. Most (61.3%) did not 
know what action to take. 126 (61.2%) patients took action, including dietary (n=101), 
physical activity (n=12) or medication (n=10) changes, or making a HCP appointment 
(n=12). High score on a Diabetes Knowledge Test was a statistically significant predictor 
of taking action (odds ratio: 2.07). However, neither taking action nor increased SMBG 
frequency were associated with improved glycaemic control. Conclusions: Responding 
to SMBG test results and increased testing frequency were not associated with improved 
glycaemic control in the short-term. There is a lack of knowledge surrounding SMBG in 
non-insulin treated patients. 
  
KEYWORDS: Type 2 diabetes, Blood Glucose Monitoring, Glycaemic control 
INTRODUCTION 
The value of self-monitoring of blood glucose (SMBG) in insulin-treated patients with 
diabetes mellitus is well established
1,2
, but its utility in non-insulin treated patients 
remains controversial. Despite this, SMBG is becoming increasingly common
3
 (and 
costly
4
) among this group of patients. Proponents of SMBG argue that it can provide ‘real 
time’ information about hyperglycemic or hypoglycemic excursions, and thus help 
patients make day-to-day behavioural choices to help keep blood glucose levels within 
clinically recommended target ranges
5
. However, there is limited empirical evidence of 
clinical benefit. A recent report from an NHS Diabetes Working Group, that included a 
systematic review of 26 RCTs and 36 observational studies, concluded that SMBG is 
associated with only minimal improvements in glycaemic control, and is unlikely to be 
effective in non-insulin treated patients
6
. SMBG is no longer routinely recommended to 
patients who do not use insulin
6,7
.  
 
What is almost universally lacking from studies on monitoring is consideration of how 
(and why) patients use self-monitoring as a self-management tool. Whether an 
appropriate response, or indeed any response at all, is made to high or low blood glucose 
readings is the key to understanding whether self-monitoring can be clinically effective
8
. 
Many insulin-using patients adjust insulin doses in response to readings, but non-insulin 
using patients cannot do this. In a large recent survey in the United States, 56% of 
patients took no action at all in response to out-of-range SMBG readings
3
. Such patients 
are unlikely to derive clinical benefit from SMBG. Heller et al (2010) have identified a 
lack of education among patients in how to interpret and use data from SMBG
6
.  
However, we raise the question as to whether there may be some groups of patients with 
type 2 diabetes mellitus who monitor regularly, have received suitable education and 
make appropriate responses to high and low readings, for whom a clinical benefit might 
be identifiable. In this cross-sectional study in Tayside, Scotland, we therefore 
administered questionnaires to patients with type 2 diabetes mellitus who had no record 
of insulin use to investigate their SMBG behaviours in detail. We then linked the 
information obtained to clinical data from a population-based diabetes clinical 
information system. We were thus able to evaluate the associations between SMBG 
behaviour (and other clinical and demographic variables) and glycaemic control.  
 
MATERIALS AND METHODS  
This study was carried out in the population of Tayside, Scotland, UK (approx. 400,000 
people). All 74 General Practices in the area were sent an invitation to assist with the 
study, of which 23 agreed. We used the SCI-DC diabetes clinical information system to 
identify patients for the study. SCI-DC (Scottish Care Information – Diabetes 
Collaboration) is a validated population-based diabetes information system in Tayside, 
Scotland, compiled by record-linking several independent data sources (formerly known 
as DARTS: Diabetes Audit and Research in Tayside, Scotland)
9
. Eligible patients within 
each participating GP practice were: aged 18 to 75 years, diagnosed with type 2 diabetes 
mellitus, had no electronic record of any prescription dispensed for insulin, had received 
at least one prescription for reagent strips for SMBG in 2009 (or in 2010 if they were 
newly diagnosed). Anonymised data only were analysed for these patients.  
 
Permission was then requested from the GP of each individual patient to collect further 
data. Patients were sent an invitation letter from their GP, an information sheet and an 
opt-out form. Those who did not return the opt-out form were contacted by a Research 
Fellow, and if they consented, were interviewed by the Research Fellow between June 
2010 and September 2011.  
 
The Research Fellow administered a set of questionnaires to the patients in their own 
homes, which took around one hour. The main questionnaires addressed SMBG 
behaviours; including timing and frequency of monitoring, understanding of blood 
glucose readings and actions taken in response to readings. Patients were asked to think 
of a time when they experienced a high or low blood glucose reading that caused them 
concern, and whether they then made any behavioural response. The questionnaire was 
developed in the light of findings from earlier qualitative work with non-insulin treated 
patients
10,11
, and also with the advice of a lay person with diabetes mellitus. It was 
subsequently piloted and refined among eight patients in one pilot practice. Other 
validated questionnaires included the MDRTC Diabetes Knowledge Test
12
, the Diabetes 
Summary of Self Care Activities
13
 and the Brief Illness Perceptions questionnaire
14
. 
Primary data collected by questionnaire were record-linked to patients’ clinical 
information on the SCI-DC clinical information system, then anonymised prior to 
analysis. Data were also assembled for patients who were not interviewed.   
 
Every patient was assigned an index date. This was either the date that they were 
interviewed, or if they were not interviewed, the date that the first patient in their practice 
was interviewed. To derive an objective measure of SMBG frequency, the number of 
reagent strips that had been dispensed in the 12 month period prior to the index date was 
calculated for every eligible patient in the study. This number was derived from total 
numbers of packs dispensed recorded on the prescription form. The most recent HbA1c 
value in the 6 month period prior to the index date of every study patient was also 
identified from SCI-DC.  
 
We investigated whether patients took action in response to test results.  Patients were 
asked whether they took action in response to ‘a [high] or [low] reading that has caused 
you concern’ and categorized according to whether or not they took action. They were 
also asked the reason for this. Possible predictors of action were then evaluated in a 
univariate logistic regression analysis, and included age, sex, SIMD deprivation quintile 
(a postcode measure of multiple material and social deprivation
15
), self-reported level of 
education, diabetes duration (as recorded on SCI-DC), diabetes knowledge (measured by 
the Diabetes Knowledge Test) and treatment (defined according to electronic records of 
prescriptions dispensed). Covariates that were statistically significant in the univariate 
analysis (p≤0.05) were then entered into a multivariate regression model.  
  
Patients with poor glycaemic control (HbA1c>=8.0% or 64mmol/mol) were identified 
and poor control was defined as the dependent variable in a binary logistic regression for 
the patients who were interviewed. In univariate analyses, we assessed whether the 
covariates defined previously were predictors of poor control; we also added in SMBG 
frequency (measured by the numbers of reagent strips dispensed for SMBG), self-
reported SMBG frequency, and whether or not the patient took action in response to test 
readings. As previously, covariates that were statistically significant (p≤0.05) in the 
univariate analysis were entered into a multivariate regression model. This process was 
then repeated for the entire sample of interviewed and non-interviewed patients.  
 
This study had ethical approval from the Tayside Committee for Medical Research Ethics 
(reference 09/S1401/48). The data of those patients who opted-out of being interviewed 
were analysed anonymously.  
 
RESULTS 
There were 629 eligible patients in 23 GP practices, of which GPs withheld permission to 
approach 61. Among the remaining patients, 111 patients actively opted-out and 225 
declined at a later stage or could not be contacted. 232 interviews were therefore 
completed, of which 207 were analysed (25 patients who had already been advised by 
their GPs to discontinue monitoring were excluded). The characteristics of the 207 
interviewed patients were compared with those of non-interviewed patients and were 
generally similar, with just over half the interviewed sample male (58%), with a mean 
age of 63 years (range 36-76 years), and mean diabetes duration of 97 months, compared 
to 56%, 60 years and 89 months respectively (Table 1). Nearly one third of interviewed 
patients had had diabetes mellitus for more than 10 years, with few (8%) diagnosed 
within the last two years. The mean number of strips dispensed in a 12 month period for 
patients who received at least some strips was 268 for the 207 interviewed patients and 
232 for non-interviewed patients, with respective medians of 200 and 150. Mean HbA1c 
was 7.45% and 7.77% respectively; this difference was statistically significant.    
 
206 of the 207 interviewed patients reported having experienced a high blood glucose 
reading, in contrast to only 109 who had experienced a low blood glucose reading. 
Among the latter, almost all reported that they had made a dietary change in response 
(e.g. consuming a biscuit or sugary drink). The 206 patients were subsequently 
categorised according to how they responded to high blood glucose readings:   
No Action: 80 (38.8%) patients reported either taking no action (n=59) or simply 
checking their blood glucose levels again later (n=21). The reason given for this by 49 
(61.3%) patients was that they did not know what action to take. Among the remaining 
patients, 22 patients were either not concerned / just accepted high readings, eight found 
that taking action made no difference and one patient found it too difficult.  
Some Action: 126 (61.2%) patients took some form of action.  These (not mutually 
exclusive) actions included making changes to diet - predominately cutting down on fats 
and sugary foods for a few days - (n = 101), increasing physical activity (n = 12), making 
changes to medication (n = 10), or making an appointment with a health care practitioner 
(n = 12). 
 
In a univariate regression analysis, females were more likely to report taking action than 
males, although this was not statistically significant in the multivariate analysis. 
However, the most important independent predictor of action appeared to be diabetes 
knowledge. Patients who scored highly in a Diabetes Knowledge Test were twice as 
likely to take action as those who scored less well.  
 
We investigated predictors of poor control in the 207 patients who were interviewed 
(Table 3) and again in the entire sample of 629 patients (Table 4). Among patients for 
whom HbA1c was available, 28.0% of interviewed patients had HbA1c ≥ 8; the figure 
was 32.6% in the entire sample.  Table 3 shows that older patients were less likely to 
have poor control, but patients treated with sulphonylureas and metformin in 
combination, or with injections of exenatide or liraglutide, were more likely to have poor 
control than patients treated with metformin only. However, SMBG frequency, whether 
measured by the number of reagent strips dispensed or by self-report, was not associated 
with glycaemic control; neither was there any discernible associaton between glycaemic 
control and diabetes knowledge, education or whether a patient took action in response to 
high results.   
 
In the larger sample, the statistically significant associations with poor glycaemic control, 
for increasing age, treatment with sulphonylureas and metformin in combination, and 
with injections, were confirmed (Table 4). Daily SMBG (measured by strips dispensed) 
was associated with poor control in the univariate analysis, but this was no longer evident 
in the multivariate model.  
DISCUSSION 
This study shows that SMBG frequency among patients with type 2 diabetes mellitus  in 
Scotland who are not treated with insulin is relatively high, with the mean number of 
reagent strips dispensed sufficient for monitoring most days. The study also suggests that 
there is a lack of knowledge surrounding SMBG among non insulin-treated patients, with 
more than one-third of a sample of 207 of such patients reporting taking no action in 
response to SMBG results. Over one half of those who reported taking no action stated 
that this was because they did not know what (or how) to do. However, a minority of 
these patients did state that they checked their blood glucose levels later if they had a 
high blood glucose reading. Although this might be considered an appropriate response, 
these patients were categorized as taking no action for subsequent analyses.   
 
In a regression model, there was an association between an objective measure of diabetes 
knowledge and whether a patient reported taking action. Patients who scored highly on 
knowledge were twice as likely to take action as those who scored less well. Although we 
cannot discount the possibility of social desirability bias (the tendency of respondents to 
distort the self-reporting of behaviour in a favourable direction, with more knowledgeable 
patients aware that reporting taking action in response to test results supports the 
expectations of health care professionals
16
), the consistent strands of evidence do suggest 
that a lack of knowledge is a key factor in whether a patient responds to test results. This 
lack of knowledge may relate to the implications of high readings, the most effective way 
to reduce SMBG readings or how to make the required behavioural changes; and may be 
because patients do not receive adequate education surrounding SMBG.  
 In regression analyses, we also evaluated possible predictors of poor glycaemic control. 
Older patients were less likely to have poor glycaemic control in both analyses, and this 
has been reported in other studies
17,18
. We also identified treatment with a combination of 
metformin and sulphonylureas, and treatment with injections of liraglutide and exenatide, 
as being associated with poor glycaemic control. This is likely to be due to patients with 
poor glycaemic control being channeled into more aggressive treatment.  
 
In terms of SMBG behavior, patients who reported taking action in response to test 
results were no less likely to have poor glycaemic control than those who did not make 
any response. There are several possible explanations for this lack of association. First, it 
may be that patients who report taking action do not actually take action (as discussed 
above). Second, it may be that the actions that patients take are ineffective. The most 
common ‘action’ was making short term changes to diet, but such reactive behavior may 
well have no discernible effect on long-term control. Third, we asked patients whether 
they took action in response to a ‘reading that has caused you concern’. However, we did 
not specifically ask patients how high their readings needed to be before they were 
‘concerned’, so it is difficult to determine whether they took action at the appropriate 
time or at an appropriate blood glucose level. However, regardless of the explanation, 
actions that patients are taking – at whatever time – are not associated with improved 
glycaemic control in the short-term. These results contrast to those of from a recent trial 
where non-insulin-using patients who adhered to a structured SMBG protocol did have 
improved glycaemic control
19
. However, this was a relatively intensive intervention 
whereby patients and clinicians collaboratively evaluated patterns of SMBG results over 
a 3-day period to plan lifestyle and medication changes; very different to observed 
practice in our study.  
 
Although there was no association between self-reported SMBG frequency and 
glycaemic control, daily monitoring as measured objectively by numbers of reagent strips 
dispensed, was associated with poor control. While this could be a reflection of patients 
with poor control motivated to monitor more frequently, the association was no longer 
evident after adjusting for treatment. It is important to recognize the potential 
confounding effect of treatment in any future cross-sectional, observational studies in this 
area.  
 
We found no associations between deprivation (in either analysis) and self-reported 
education level and poor glycaemic control, in contrast to other studies
17,18
. This is 
perhaps surprising given the well-established associations between disadvantage and poor 
outcomes in diabetes
20
. However, it may be that the measures that we used were not 
sensitive enough to discriminate sufficiently between patients, therefore diluting any 
effects that were present.  
  
The study was carried out with a self-selected sample of patients who agreed to be 
interviewed. We did not specifically ask why some patients did not wish to be 
interviewed, but the demographic characteristics of the interviewed patients were similar 
to those of the total population. Despite this, we cannot exclude the possibility that their 
SMBG behaviour was different. The mean number of strips dispensed to them was 
indeed slightly higher. They also had lower HbA1c, and could perhaps have been more 
motivated, interested in and positive about SMBG. If this is the case, however, then the 
lack of knowledge identified among these possibly more motivated patients is even more 
concerning. Also, it is noteworthy that other associations that were identified in the 
smaller self-selected group for glycaemic control were confirmed in the entire sample of 
non-selected patients.  
 
Data for the study came from self-report measures and from electronic records of clinical 
data from SCI-DC. All patients were interviewed by the same Research Fellow who 
adhered to a pre-defined protocol for administering the questionnaires. While these 
questionnaires were either existing, validated measures, or ones that had been developed 
and tested with a lay service user with diabetes mellitus and then refined in a pilot study, 
we can not be completely certain that patients gave accurate responses to questions asked. 
Further studies conducted on a larger scale may therefore benefit from a more in-depth 
assessment of content validity to ensure items are collecting responses as intended. In 
contrast, SCI-DC is a validated population-based clinical information system that has 
been widely used in epidemiological research, and we are confident in data derived from 
it. However, in terms of reagent strips dispensed for SMBG, while we know that patients 
were dispensed the strips, we cannot be sure that they actually used them. They may also 
have received strips from other sources. We also identified 43 interviewed patients who 
had received no reagent strips in the 12 month period prior to their index date; although 
receiving strips in 2009 was an eligibility criterion, as was self-reported current 
monitoring. It is possible that they had stocks of reagent strips dispensed previously, 
and/or they were monitoring very infrequently, and indeed a similar number self-reported 
infrequent monitoring. In general though, the numbers of strips dispensed were higher 
than those reported in earlier studies in Tayside
21
, suggesting that most of the interviewed 
patients received enough strips to monitor at least 3-4 times per week, and tallying fairly 
well with self-report frequency.  
 
This was a cross-sectional study in that all the data were collected from interviewed 
patients at the same point in time. This can mean that it is difficult to determine the order 
in which particular events or outcomes occurred. However, HbA1c values were 
electronically recorded and we identified the HbA1c measure nearest in time over a 6-
month period prior to the date of the patient’s interview. This was in order to relate the 
HbA1c measure in time to the SMBG practices that patients were describing.  
 
We believe that the associations we identified in this study are valid. However, the 
number of interviewed patients was relatively small, so it is possible that the study was 
not sufficiently powered to detect some associations which were relatively large. For 
example, with a sample size of 207, divided equally between two groups, the study had 
80% power to detect differences in categorical variables of around 14%. A larger sample 
would be needed to detect smaller differences. Despite this limitation, we have gone 
further than other studies in attempting to characterize how patients monitor and respond 
to test results. Despite this, the study still gives a strong indication that SMBG, as 
currently practised in Tayside, is not associated with improved glycaemic control in the 
short-term, and highlights the lack of knowledge surrounding SMBG in non-insulin 
treated patients with type 2 diabetes mellitus. It is also important to establish whether 
these results would be replicated in other regions and countries.  
 
The American Association of Diabetes Educators has recently made a call for all patients 
with diabetes to receive standardised and tailored education on SMBG, advocating that 
‘safe and appropriate blood glucose monitoring methods need to be taught including self-
management skills that incorporate and utilize the data obtained from blood glucose 
monitoring for an individualized program of self care’22.  This should not only include 
education on the mechanics of operating meters, how often to test, and how to record the 
results, but also what to do with blood glucose results, target blood glucose goals, and 
when to test. Similarly, one of the key recommendations from NHS Diabetes (2010)
6
 is 
that  ‘SMBG should only be used within a care package, accompanied by structured 
education which should include clear instructions as to the place of monitoring and how 
results can be used to reinforce lifestyle change, adjust therapy or alert health 
professionals’. The results from our study strongly support these recommendations.  
 
  
 
ACKNOWLEDGEMENTS 
We thank the patients who agreed to be interviewed for this project and the General 
Practitioners in Tayside, Scotland, who facilitated contact with them. We also thank our 
lay user representative who was involved at all stages of the project and the Health 
Informatics Centre, University of Dundee, for data provision. Dr Josie Evans is the 
guarantor of the study.  
 
.  
 
DECLARATION OF COMPETING INTERESTS 
No Conflicts of Interest have been declared by the authors.  
 
 
REFERENCES 
 
1. Scottish Intercollegiate Guidelines Network (SIGN) (2010). Management of 
diabetes. A national clinical guideline. 116.  
2. Reynolds RM, Webb DJ. Recommendations and conclusions from a mini-
symposium on self-blood glucose monitoring. J R Coll Physicians Edinb 
2006;36:155-8. 
3. Polonsky WH, Fisher L, Hessler D, Edelman SV. A survey of blood glucose 
monitoring in patients with type 2 diabetes: are recommendations from health care 
professionals being followed? Current Medical Research & Opinion 2011; 
27(S3): 31-37. 
4. Reynolds RM, Strachan MWJ. Home blood glucose monitoring in type 2 
diabetes. Br Med J 2004;329:754-755.  
5. Boutati EI, Raptis SA. Self-monitoring of blood glucose as part of the integral 
care of type 2 diabetes. Diabetes Care 2009; Suppl 2:S205-10.  
6. Heller S et al. A report prepared by an NHS Diabetes Working Group. Self 
monitoring of blood glucose in non-insulin-treated type 2 diabetes. NHS Diabetes, 
2010.  
7. Clar C, Barnard K, Cummins E, Royle P, Waugh N. Self-monitoring of blood 
glucose in type 2 diabetes: systematic review. Health Technol Assess 2010; 14.   
8. Ipp E, Aquino RL, Christenson P. Point: Self-monitoring of blood glucose in type 
2 diabetes not receiving insulin. The sanguine approach. Diabetes Care 2005; 
28:1528-1530.  
9. Morris AD, Boyle DIR, MacAlpine R et al. The diabetes audit and research in 
Tayside, Scotland (DARTS) study: electronic record-linkage to create a diabetes 
register. Br Med J 1997; 315:524528. 
10. Peel E, Douglas M, Lawton J. Self-monitoring of blood glucose in type 2 
diabetes: Longitudinal qualitative study of patients’ perspectives. Br Med J 2007; 
doi:10.1136/bmj.39302.444572.DE 
11. Peel E, Parry O, Douglas M, Lawton J. Blood glucose self-monitoring in non-
insulin treated type 2 diabetes: qualitative study of patients’ perspectives. British 
Journal of General Practice 2004, 54: 183-188. 
12. Fitzgerald JT, Anderson RM, Funnell MM, Hiss RG, Hess GE, Davis WK, Barr 
PA. The reliability and validity of a brief diabetes knowledge test.  
13. Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care 
activities measure: results from 7 studies and a revised scale. Diabetes Care 2000; 
23:943-950. 
14. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perceptions 
questionnaire. J  Psychosomatic Res 2006; 60:631-637.  
15. Using the Scottish Index of Multiple Deprivation 2006: Guidance leaflet. 
http://www.scotland.gov.uk/Publications/2006/10/13142841/1. 
16. van de Mortel TF. Faking it: social desirability response bias in self-report 
research. Australian Journal of Advanced Nursing 2005; 25:40-48.  
17. Benoit SR, Fleming R, Philis-Tsimikas A, Ming J. Predictors of glycemic control 
among patients with Type 2 diabetes: A longitudinal study. BMC Public Health 
2005; 5:36.   
18. Goudswaard AN, Stolk RP, Zuithoff P, Rutten GEHM. Patient characteristics do 
not predict poor glycemic control in type 2 diabetes patients treated in primary 
care. Eur J Epidemiol 2004; 19:541-545. 
19. Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, 
Wagner RS. Structured self monitoring of blood glucose significantly reduces 
A1C levels in poorly controlled, noninsulin- treated type 2 diabetes. Results from 
the Structured Testing Program Study. Diabetes Care; 2011:34:262-267. 
20. Brown AF, Ettner SL, Piette J, Weinberger M, Gregg E, Shapiro MF, Karter AJ, 
Safford M, Waitzfelder B, Prata PA, Beckles GL: Socioeconomic position and 
health among persons with diabetes mellitus: a conceptual framework and review 
of the literature. Epidemiol Rev 26:63–77, 2004 
21. Evans JMM, Mackison D, Emslie-Smith A, Lawton J. Self-monitoring of blood 
glucose in type 2 diabetes: Cross-sectional analyses in 1993, 1999 and 2009. 
Diabetic Medicine 2012; 29:1-4. 
22. American Association of Diabetes Educators. AADE Position Statement: Self-
monitoring of blood glucose.  Diabetes Care 2009; 1:s17-19. 
 
 
Table 1: Characteristics of study population, and those who were interviewed  
 
 629 patients 
identified by HIC as 
eligible for the study 
207 interviewed 
patients who still 
self-monitored 
422 non-interviewed 
patients (or who no 
longer monitored)  
 No (%) No (%) No(%) 
Sex   
Males 355 (56.4) 119 (57.5) 236 (55.9) 
Females 274 (43.6) 88 (42.5) 186 (44.1) 
Age    
< 50 years 98 (15.6) 20 (9.7) 78 (18.5) 
50-59 years 154 (24.5) 43 (20.8) 111 (26.3) 
60-69 years 234 (37.2) 85 (41.1) 149 (35.3) 
70-76 years 143 (22.7) 59 (28.5) 84 (19.9) 
Mean age 61 years (SD 10) 63 years (SD 9) 60 years (SD 10) 
Diabetes duration   
Less than 2 years 80 (12.7) 17 (8.2) 63 (14.9) 
2-5 years 187 (29.7) 67 (32.4) 120 (28.4) 
6-9 years 201 (32.0) 63 (30.4) 138 (32.7) 
10 years + 161 (25.6) 60 (29.0) 101 (23.9) 
Mean duration (months) 95 months (SD 67) 97 months (SD 66) 89 months (SD 68) 
SIMD Quintile
1   
1 (most deprived) 88 (14.0) 24 (11.6) 64 (15.2) 
2 110 (17.5) 37 (17.9) 73 (17.3) 
3 119 (18.9) 33 (15.9) 86 (20.4) 
4 189 (30.0) 72 (34.8) 117 (27.7) 
5 (least deprived) 107 (17.0) 38 (18.4) 69 (16.4) 
Treatment
   
Metformin
2
  182 (28.9) 56 (27.1) 126 (29.9) 
Sulphonylurea
3
  55 (8.7) 17 (8.2) 38 (9.0) 
Metformin and 
sulphonylurea 
272 (43.2) 92 (44.4) 180 (42.7) 
Injections of exenatide 
or liraglutide 
64 (10.2) 26 (12.6) 38 (9.0) 
Diet / lifestyle only 53 (8.4) 15 (7.2) 38 (9.0) 
Reagent strips 
dispensed
4 
  
Number who received 
any strips in 12 month 
prior to interview 
447 (74.8) 162 (78.6) 285 (72.9) 
Mean strips dispensed 245 (SD 222) 268 (SD 222) 232 (221) 
Median strips dispensed 200 200 150 
HbA1C data
5  
Mean HbA1c
6 
7.66 (SD  1.6) 7.45 (SD  1.4) 7.77  (SD 1.7) 
Median HbA1c 7.30 7.10 7.40 
1
SIMD Scotland Quintile (SIMD - Scottish index of multiple deprivation). Identified based on patient's full 
postcode at the date of interview; available for 613 of 629 patients and 204 of 207 patients respectively. 
2
Or combined with pioglitazone, rosiglitazone, sitagliptin 
3
Or combined with pioglitazone, rosiglitazone, sitagliptin, saxagliptin 
 
4
Only patients with at least 12 months diabetes duration included (597,205 and 391 patients respectively).  
5 
Most recent HbA1c value in the 6 months prior to index date (excluding outlying values > 20)   
6
An independent samples t test indicated that the difference in mean HbA1c between interviewed and non-
interviewed patients was statistically significant (p = 0.03)  
 
 
Table 2: Results of binary logistic regression for whether a patient reported taking 
action in response to test results (n = 207) 
 
 Total No (%) 
that took 
action 
Unadjusted odds 
ratio (95% CI) 
p 
value 
Adjusted odds 
ratio (95% CI) 
p 
value 
Sex 
Males 119 67 (56.3) 1.00  1.00  
Females 88  59 (67.0) 1.64 (0.92-2.91) 0.09 1.46 (0.80-2.67) 0.22 
Age 
<50 20  14 (70.0) 1.00  - - 
50-59 43  31 (72.1) 1.11 (0.35-3.55) 0.86 - - 
60-69 85  46 (54.1) 0.52 (0.18-1.48) 0.22 - - 
>70  59  35 (59.3) 0.63 (0.21-1.86) 0.40 - - 
SIMD  
1 (most 
deprived) 
24  14 (58.3) 1.00  - - 
2 37  27 (73.0) 2.14 (0.71-6.49) 0.18 - - 
3 33  17 (51.5) 0.76 (0.26-2.19) 0.61 - - 
4 72  47 (65.3) 1.34 (0.52-3.46) 0.54 - - 
5 (least 
deprived) 
38  20 (52.6) 0.79 (0.28-2.23) 0.66 -  
Education / qualifications    
None / school 
level   
101 61 (60.4) 1.00  - - 
Post school / 
diploma 
73  42 (57.5) 0.87 (0.47-0.61) 0.65 - - 
Professional / 
degree  
32  22 (68.8) 1.41 (0.60-3.29) 0.43 - - 
Diabetes Duration 
< 2 years 17  9 (52.9) 1.00    
2-5 years 67  42 (62.7) 1.59 (0.51-4.37) 0.46 - - 
6-9 years 63  36 (57.1) 1.23 (0.42-3.62) 0.71 - - 
>10 years 60 39 (65.0) 1.65 (0.56-4.91) 0.37 - - 
Knowledge 
0-10 148  83 (56.1) 1.00  1.00  
11-13 51  38 (74.5) 2.25 (1.11-4.58) 0.03 2.07 (1.00 - 4.26) 0.05 
Treatment       
Metformin 56 30 (53.6) 1.00    
Sulph 17 7 (41.2) 0.58 (0.19–1.76) 0.34 - - 
Met / sulph 92 60 (65.2) 1.57 (0.79-3.09) 0.20 - - 
Injections  26 18 (69.2) 1.88 (0.70-5.03) 0.21 - - 
Diet/lifestyle 15 11 (73.3) 2.29 (0.65-8.09) 0.20 - - 
 
 
 
  
Table 3: Results of binary logistic regression for glycaemic control (HbA1c>= 8 as 
dependent variable) for 193 of 629 eligible patients who were interviewed and had 
an HbA1c value recorded 
 
 Total No (%) 
HbA1c 
>=8 
Unadjusted odds 
ratio (95% CI) 
p 
value 
Adjusted odds 
ratio (95% CI) 
p 
value 
Sex 
Males 108 32 (29.6) 1.00  - - 
Females 85  21 (24.7) 0.77 (0.40-1.47) 0.42 - - 
Age 
<50 20  9 (45.0) 1.00  1.00  
50-59 36  14 (38.9) 0.78 (0.26-2.35) 0.66 1.19 (0.35-4.09) 0.78 
60-69 79  20 (25.3) 0.41 (0.15-1.15) 0.09 0.76 (0.24-2.39) 0.64 
>70  58  10 (17.2) 0.26 (0.08-0.78) 0.02 0.44 (0.13-1.52) 0.20 
SIMD 
1 (most 
deprived) 
22  5 (22.7) 1.00  - - 
2 34  10 (29.4) 1.42 (0.41-4.90) 0.58 - - 
3 33  9 (27.3) 1.28 (0.36-4.48) 0.71 - - 
4 66  22 (33.3) 1.70 (0.55-5.21) 0.35 - - 
5 (least 
deprived) 
35  7 (20.0) 0.85 (0.23-3.11) 0.81 -  
Diabetes Duration 
< 2 years 13 2 (15.4) 1.00  - - 
2-5 years 62 14 (22.6) 1.60 (0.32-8.11) 0.57 - - 
6-9 years 61 19 (31.1) 2.49 (0.50-12.34) 0.27 - - 
>10 years 57 18 (31.6) 2.54 (0.51-12.66) 0.26 - - 
Treatment       
Metformin 52 9 (17.3) 1.00  1.00  
Sulph 17 1 (5.9) 0.32 (0.04-2.73) 0.30 0.44 (0.05-3.91) 0.46 
Met / sulph 86 27 (31.4) 2.22 (0.95-5.21) 0.07 2.53 (1.05-6.08) 0.04 
Injections 24 13 (54.2) 5.65 (1.92-16.59) 0.02 5.19 (1.73-15.59) 0.003 
Diet/lifestyle 13 1 (7.7) 0.40 (0.05-3.46) 0.40 0.42 (0.05-3.66) 0.03 
Frequency       
No strips 43 13 (30.2) 1.00    
 < Once per 
week 
13 2 (15.4) 0.42 (0.08-2.17) 0.30 - - 
1-4 times per 
week 
65 17 (26.2) 0.82 (0.35-1.92) 0.64 - - 
4-7 times per 
week 
35 7 (20.0) 0.58 (0.20-1.65) 0.31 - - 
At least daily 35 12 (34.3) 1.20 (0.46-3.13) 0.70 - - 
Self-
reported 
      
frequency  
Rarely/occasi
onally 
42 11 (26.2) 1.00  - - 
Most weeks 26 9 (34.6) 1.49 (0.52-4.31) 0.46 - - 
Every week 56 9 (16.1) 0.54 (0.20-1.45) 0.22 - - 
Most days 12 5 (41.7) 2.01 (0.53-7.67) 0.31 - - 
At least daily  57 19 (33.3) 1.41 (0.58-3.40) 0.45 - - 
Self-reported action      
No action 74 19 (25.7) 1.00  - - 
Action  118 34 (28.8) 1.17 (0.61-2.26) 0.64 - - 
Diabetes Knowledge      
Low score 135 37 (27.4) 1.00  - - 
High score 50 13 (26.0) 0.93 (0.45-1.94) 0.85 - - 
Education       
None/school 
level 
79 21 (26.6) 1.00  - - 
Post school / 
diploma 
15 5 (33.3) 1.38 (0.42-4.51) 0.59 - - 
Professional 
/ degree 
98 26 (26.5) 1.00 (0.51-1.95)  0.99 - - 
 
Table 4: Results of binary logistic regression for glycaemic control (HbA1c>= 8) as 
dependent variable) for 562 of 629 eligible patients with an HbA1c value recorded  
 
 Total No (%) 
HbA1c 
>=8 
Unadjusted odds 
ratio (95% CI) 
P 
value 
Adjusted odds 
ratio (95% CI) 
P 
value 
Sex 
Males 315 105 (33.3) 1.00  - - 
Females 247  78 (31.6) 0.92 (0.65-1.32) 0.66 - - 
Age 
<50 79  36 (45.6) 1.00  1.00  
50-59 131  55 (42.0) 0.86 (0.49-1.52) 0.61 1.02 (0.55-1.92) 0.95 
60-69 216  61 (28.2) 0.47 (0.28-0.80) 0.01 0.50 (0.28-0.91) 0.02 
>70  135  31 (23.0) 0.35 (0.19-0.64) 0.00 0.31 (0.16-0.59) 0.00 
SIMD 
1 (most 
deprived) 
70  26 (37.1) 1.00  - - 
2 100  34 (34.0) 0.87 (0.46-1.65) 0.67 - - 
3 111  38 (34.2) 0.88 (0.47-1.64) 0.69 - - 
4 171  56 (32.7) 0.82 (0.46-1.47) 0.51 - - 
5 (least 
deprived) 
94  27 (28.7) 0.68 (0.35-1.32) 0.26 -  
Diabetes Duration 
< 2 years 66 23 (34.8) 1.00  - - 
2-5 years 162 45 (27.8) 0.72 (0.39-1.33) 0.29 - - 
6-9 years 180 63 (35.0) 1.01 (0.56-1.82) 0.98 - - 
>10 years 154 52 (33.8) 0.95 (0.52-1.75) 0.88 - - 
Treatment       
Metformin 166 22 
(13.3%) 
1.00  1.00  
Sulph 48 11 
(22.9%) 
1.95 (0.87-4.37) 0.11 2.57 (1.10-6.00) 0.03 
Met / sulph 247 106 
(42.9%) 
4.92 (2.94-8.23) <0.01 5.95 (3.47-10.20) <0.0
1 
Injections of  61 38 
(62.3%) 
10.81 (5.45-21.46) <0.01 10.27 (5.03-2.94) <0.0
1 
Diet/lifestyle  37 5 (13.5%) 1.03 (0.36-2.91) 0.97 1.04 (0.36-3.00) 0.95 
Frequency       
No strips 136 40 
(29.4%) 
1.00  1.00  
< Once per 
week   
55 17 
(30.9%) 
1.07 (0.54-2.12) 0.84 0.96 (0.45-2.06) 0.93 
1-4 times per 
week 
202 63 
(31.2%) 
1.09 (0.68-1.75) 0.73 0.91 (0.54-1.54) 0.73 
4-7 times per 
week 
77 22 
(28.6%) 
0.96 (0.52-1.78) 0.90 0.66 (0.34-1.31) 0.24 
At least daily 92 41 
(44.6%) 
1.93 (1.11-3.35) 0.02 1.24 (0.67-2.31) 0.50 
       
       
 
